Table 2 Serum levels of PIVKA-II and AFP and the serum γ-GT/ALT ratio in patients with CHB, early-stage HCC, and advanced HCC.

From: Diagnostic value of the γ-glutamyltransferase and alanine transaminase ratio, alpha-fetoprotein, and protein induced by vitamin K absence or antagonist II in hepatitis B virus-related hepatocellular carcinoma

 

CHB (n = 396)

Early-stage HCC (n = 94)

Advanced HCC (n = 140)

P value

PIVKA-II (mAU/mL)

22.32 (15.96–36.84)

342.19 (53.56–4,208.13)a

15,701.03 (1,843.90–30,000.00)ab

0.000

AFP (ng/mL)

30.45 (5.32–117.43)

66.20 (7.63–1,718.80)a

1,767.60 (115.83–33,996.28)ab

0.000

γ-GT/ALT

0.57 (0.23–1.25)

2.13 (1.11–5.03)a

4.15 (1.91–6.36)ab

0.000

  1. Data are expressed as medians (interquartile ranges).
  2. CHB chronic hepatitis B, HCC hepatocellular carcinoma, PIVKA-II protein induced by vitamin K absence or antagonist II, AFP alpha-fetoprotein, γ-GT/ALT the ratio of γ-glutamyltransferase to alanine aminotransferase.
  3. aVersus CHB.
  4. bVersus early-stage HCC.
Back to article page